RA Capital Reduces Stake Below 5% in Werewolf Therapeutics
HOWL sits 22% above its 52-week low of $0.27.
Summary
Major institutional investor RA Capital Management sold an additional $316,000 in Werewolf Therapeutics stock, reducing its stake below the 5% reporting threshold.
Key Events · Ownership and Investor Activity · HOWL
-
Significant Share Sales
RA Capital Management sold approximately 936,543 shares for a total value of about $316,247 between June 29 and July 2, 2026.
-
Ownership Below 5% Threshold
As a result of these sales, RA Capital Management ceased to be a beneficial owner of more than 5% of Werewolf Therapeutics' common stock as of June 30, 2026.
-
Continued Institutional Distribution
This filing extends a recent trend of institutional investors, including RA Capital, reducing their positions in the company, with net insider sales of nearly $2 million over the last 90 days.
Analysis · HOWL · Life Sciences
RA Capital Management, a significant institutional investor, has further reduced its holdings in Werewolf Therapeutics, selling approximately $316,000 worth of shares. This latest round of sales caused the firm to drop below the 5% beneficial ownership threshold as of June 30, 2026, signaling a continued reduction in their investment in the company. This follows a pattern of distribution by institutional investors over the past 90 days.
At the time of this filing, HOWL was trading at $0.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.5M. The 52-week trading range was $0.27 to $2.38. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.